Wilson, M.-M.; Henshall,D.C.; Byrne, S.M.; Brennan, G.P.CHD2-Related CNS Pathologies.Int.J. Mol. Sci.2021,22, 588. https://doi.org/10.3390/
Epileptic encephalopathies (EE) are severe epilepsy syndromes characterized by multiple seizure types, developmental delay and even regression. This class of disorders are increasingly being identified as resulting from de novo genetic mutations including many identified mutations in the family of chromodomain helicase DNA binding (CHD) proteins. In particular, several de novo pathogenic mutations have been identified in the gene encoding chromodomain helicase DNA binding protein 2 (CHD2), a member of the sucrose nonfermenting (SNF-2) protein family of epigenetic regulators. These mutations in the CHD2 gene are causative of early onset epileptic encephalopathy, abnormal brain function, and intellectual disability. Our understanding of theme chanisms by which modification or loss of CHD2 cause this condition remains poorly understood. Here, we review what is known and still to be elucidated as regards the structure and function ofCHD2 and how its dysregulation leads to a highly variable range of phenotypic presentations.
Courtesy of Researchgate